$PLX
Protalix BioTherapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000155837021011752 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $6.427M $10.97M $21.65M
YoY Change -41.4% -10.45% 107.34%
Cost Of Revenue $4.733M $1.827M $3.426M
YoY Change 159.06% -32.21% 67.53%
Gross Profit $1.694M $9.140M $18.22M
YoY Change -81.47% -4.31% 117.16%
Gross Profit Margin 26.36% 83.34% 84.17%
Selling, General & Admin $3.171M $2.194M $3.187M
YoY Change 44.53% 6.09% 42.91%
% of Gross Profit 187.19% 24.0% 17.49%
Research & Development $7.689M $9.186M $10.34M
YoY Change -16.3% -31.05% -11.63%
% of Gross Profit 453.9% 100.5% 56.75%
Depreciation & Amortization $280.0K $330.0K $376.0K
YoY Change -15.15% -10.81% -7.16%
% of Gross Profit 16.53% 3.61% 2.06%
Operating Expenses $10.86M $11.38M $13.53M
YoY Change -4.57% -26.06% -2.9%
Operating Profit -$9.166M -$2.240M $4.693M
YoY Change 309.2% -61.64% -184.8%
Interest Expense -$2.080M -$1.910M -$3.030M
YoY Change 8.9% 0.53% 75.14%
% of Operating Profit -64.56%
Other Income/Expense, Net -$2.075M -$1.910M -$3.026M
YoY Change 8.64% 0.32% 74.91%
Pretax Income -$11.24M -$4.150M $1.670M
YoY Change 170.84% -46.38% -123.0%
Income Tax
% Of Pretax Income
Net Earnings -$11.24M -$4.150M $1.667M
YoY Change 170.87% -46.4% -122.95%
Net Earnings / Revenue -174.9% -37.84% 7.7%
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25 -$0.13 $0.10
COMMON SHARES
Basic Shares Outstanding 45.44M
Diluted Shares Outstanding 45.44M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.90M $4.800M $14.20M
YoY Change 606.25% -80.88% -53.29%
Cash & Equivalents $33.88M $4.843M $14.17M
Short-Term Investments
Other Short-Term Assets $3.013M $2.893M $25.20M
YoY Change 4.15% 31.5% 1377.14%
Inventory $13.64M $11.07M $9.500M
Prepaid Expenses
Receivables $2.330M $5.262M $8.900M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $95.92M $54.21M $57.80M
YoY Change 76.95% 30.31% 22.09%
LONG-TERM ASSETS
Property, Plant & Equipment $4.991M $4.793M $10.70M
YoY Change 4.13% -59.38% 76.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.900M $7.000M $14.40M
YoY Change -72.86% 268.42% 700.0%
Total Long-Term Assets $12.28M $17.50M $25.10M
YoY Change -29.82% 28.68% 83.17%
TOTAL ASSETS
Total Short-Term Assets $95.92M $54.21M $57.80M
Total Long-Term Assets $12.28M $17.50M $25.10M
Total Assets $108.2M $71.71M $82.90M
YoY Change 50.89% 29.91% 35.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.100M $6.700M $9.400M
YoY Change -8.96% 0.0% 59.32%
Accrued Expenses $1.200M $1.100M $1.100M
YoY Change 9.09% -8.33% -15.38%
Deferred Revenue $18.11M $18.35M
YoY Change -1.32%
Short-Term Debt $0.00 $4.300M $4.300M
YoY Change -100.0%
Long-Term Debt Due $56.40M
YoY Change
Total Short-Term Liabilities $96.25M $42.42M $47.60M
YoY Change 126.92% 63.13% 76.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $52.70M $52.00M
YoY Change -100.0% -3.66% -3.7%
Other Long-Term Liabilities $38.00K $124.0K $14.10M
YoY Change -69.35% -99.7% 166.54%
Total Long-Term Liabilities $8.116M $64.06M $66.10M
YoY Change -87.33% -33.75% -29.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $96.25M $42.42M $47.60M
Total Long-Term Liabilities $8.116M $64.06M $66.10M
Total Liabilities $104.4M $106.5M $113.8M
YoY Change -1.98% -13.22% -5.87%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.841M -$34.76M -$30.88M
YoY Change
Total Liabilities & Shareholders Equity $108.2M $71.71M $82.90M
YoY Change 50.89% 29.91% 35.8%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$11.24M -$4.150M $1.667M
YoY Change 170.87% -46.4% -122.95%
Depreciation, Depletion And Amortization $280.0K $330.0K $376.0K
YoY Change -15.15% -10.81% -7.16%
Cash From Operating Activities $6.510M -$7.830M -$7.117M
YoY Change -183.14% 51.45% -2.19%
INVESTING ACTIVITIES
Capital Expenditures $280.0K $210.0K $66.00K
YoY Change 33.33% 425.0% -61.18%
Acquisitions
YoY Change
Other Investing Activities $7.820M -$60.00K $35.00K
YoY Change -13133.33% 0.0% -369.23%
Cash From Investing Activities $7.540M -$270.0K -$35.08M
YoY Change -2892.59% 170.0% 9355.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -1.270M 38.61M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 6.510M -7.830M -7.117M
Cash From Investing Activities 7.540M -270.0K -35.08M
Cash From Financing Activities 0.000 -1.270M 38.61M
Net Change In Cash 14.05M -9.370M -3.626M
YoY Change -249.95% 77.8% -52.58%
FREE CASH FLOW
Cash From Operating Activities $6.510M -$7.830M -$7.117M
Capital Expenditures $280.0K $210.0K $66.00K
Free Cash Flow $6.230M -$8.040M -$7.183M
YoY Change -177.49% 54.32% -3.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
696-9345
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
PLX
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45556647
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33882000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18265000
CY2021Q2 plx Short Term Bank Deposits
ShortTermBankDeposits
43058000
CY2020Q4 plx Short Term Bank Deposits
ShortTermBankDeposits
20280000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2330000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
3013000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2096000
CY2021Q2 us-gaap Inventory Net
InventoryNet
13640000
CY2020Q4 us-gaap Inventory Net
InventoryNet
13082000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
95923000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
55723000
CY2021Q2 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1884000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4991000
us-gaap Cost Of Revenue
CostOfRevenue
5253000
CY2020Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1799000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
4733000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4845000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5406000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5567000
CY2021Q2 us-gaap Assets
Assets
108204000
CY2020Q4 us-gaap Assets
Assets
67934000
CY2021Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6128000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7221000
CY2021Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
14420000
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
13926000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1235000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1420000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18109000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5394000
CY2021Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
56355000
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
54427000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4086000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
96247000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86474000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1269000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1716000
CY2021Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2302000
CY2020Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2263000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4507000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4467000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8116000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8497000
CY2021Q2 us-gaap Liabilities
Liabilities
104363000
CY2020Q4 us-gaap Liabilities
Liabilities
94971000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3841000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108204000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67934000
us-gaap Revenues
Revenues
17747000
us-gaap Revenues
Revenues
32613000
CY2021Q2 us-gaap Revenues
Revenues
6427000
CY2020Q2 us-gaap Revenues
Revenues
10967000
us-gaap Cost Of Revenue
CostOfRevenue
9498000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
1827000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14811000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19526000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7689000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9186000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6309000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5381000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3171000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2194000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12871000
us-gaap Operating Income Loss
OperatingIncomeLoss
2453000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9166000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37625000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
8575000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
832000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
562000
us-gaap Net Income Loss
NetIncomeLoss
-16716000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3841000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-30881000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2240000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4240000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
5177000
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2203000
CY2020Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1948000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
344000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
241000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
128000
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
38000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3896000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4936000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2075000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1910000
us-gaap Other Income
OtherIncome
51000
us-gaap Net Income Loss
NetIncomeLoss
-16716000
us-gaap Net Income Loss
NetIncomeLoss
-2483000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11241000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4150000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42744426
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19923935
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45436907
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32442636
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
plx Issuance Of Common Stock And Warrants Net Of Issuance Cost Value
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
41343000
plx Adjustments To Additional Paid In Capital Receivables From Sale Of Common Stock And Warrants
AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants
4000000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
698000
us-gaap Net Income Loss
NetIncomeLoss
-2483000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34764000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
267000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4150000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34764000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14504000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
322000
CY2021Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
256000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11241000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3841000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
53000
plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
-359000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
54000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
69000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23144000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35347000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4086000
plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37625000
plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37343000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8575000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42114000
us-gaap Net Income Loss
NetIncomeLoss
-16716000
us-gaap Net Income Loss
NetIncomeLoss
-2483000
us-gaap Share Based Compensation
ShareBasedCompensation
1394000
us-gaap Share Based Compensation
ShareBasedCompensation
698000
us-gaap Depreciation
Depreciation
574000
us-gaap Depreciation
Depreciation
710000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
121000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
250000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
70000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
107000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
56000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-22000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
51000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1928000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1665000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12268000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10841000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1587000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1621000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-94000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-27000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
558000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2910000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-544000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
309000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-13000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-385000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3318000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14952000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
37835000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
35000000
plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
15000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
667000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
278000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37343000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-35000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
7000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15617000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12949000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18265000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17792000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33882000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4843000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
372000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
50000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
232000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
362000
plx Note Receivable From Issuance Of Common Stock And Warrants Net Of Issuance Cost
NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
4000000
plx Interest Received Net
InterestReceivedNet
307000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8749999
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40200000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.60
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18445764
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26322164
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25997289
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25874641
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3046000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3347000
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3065000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2887000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7529000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6848000
CY2021Q2 us-gaap Inventory Net
InventoryNet
13640000
CY2020Q4 us-gaap Inventory Net
InventoryNet
13082000

Files In Submission

Name View Source Status
0001558370-21-011752-index-headers.html Edgar Link pending
0001558370-21-011752-index.html Edgar Link pending
0001558370-21-011752.txt Edgar Link pending
0001558370-21-011752-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20210630.xsd Edgar Link pending
plx-20210630x10q.htm Edgar Link pending
plx-20210630x10q005.jpg Edgar Link pending
plx-20210630x10q006.jpg Edgar Link pending
plx-20210630x10q007.jpg Edgar Link pending
plx-20210630x10q_htm.xml Edgar Link completed
plx-20210630xex31d1.htm Edgar Link pending
plx-20210630xex31d2.htm Edgar Link pending
plx-20210630xex32d1.htm Edgar Link pending
plx-20210630xex32d2.htm Edgar Link pending
plx-20210630_cal.xml Edgar Link unprocessable
plx-20210630_def.xml Edgar Link unprocessable
plx-20210630_lab.xml Edgar Link unprocessable
plx-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending